122 related articles for article (PubMed ID: 1634643)
1. Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers.
Hutt V; Theodor R; Pabst G; Bonn R; Fritschi E; Jaeger H
J Clin Pharmacol; 1992 Jun; 32(6):553-7. PubMed ID: 1634643
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the pharmacokinetics and absolute bioavailability of three isosorbide-5-mononitrate preparations in healthy volunteers.
Hutt V; Bonn R; Fritschi E; Jaeger H
Arzneimittelforschung; 1995 Feb; 45(2):142-5. PubMed ID: 7710435
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability and pharmacokinetics of a new isosorbide dinitrate spray preparation in healthy volunteers.
Hutt V; Theodor R; Pabst G; Lutz D; Bonn R; Fritschi E
Arzneimittelforschung; 1993 Aug; 43(8):842-6. PubMed ID: 8216439
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers.
Niopas I; Daftsios AC; Nikolaidis N
Arzneimittelforschung; 2002; 52(3):182-6. PubMed ID: 11963645
[TBL] [Abstract][Full Text] [Related]
5. Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.
Niopas I; Daftsios AC; Nikolaidis N
Int J Clin Pharmacol Ther; 2001 May; 39(5):224-8. PubMed ID: 11380069
[TBL] [Abstract][Full Text] [Related]
6. [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
Scheidel B; Blume H; Stenzhorn G; Siewert M; Babej-Dölle RM
Arzneimittelforschung; 1991 Mar; 41(3):212-8. PubMed ID: 1867657
[TBL] [Abstract][Full Text] [Related]
7. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
Vree TB; Dammers E; Valducci R
Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
[TBL] [Abstract][Full Text] [Related]
8. [Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation].
Metzner JE; Buchberger D; Häring N; Läuter J
Arzneimittelforschung; 1997 Jun; 47(6):719-26. PubMed ID: 9281301
[TBL] [Abstract][Full Text] [Related]
9. Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
Arzneimittelforschung; 1998 Jun; 48(6):641-5. PubMed ID: 9689420
[TBL] [Abstract][Full Text] [Related]
10. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
Sata H; Inoue K; Nii T; Kuroda T
Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575
[TBL] [Abstract][Full Text] [Related]
11. [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
Yao Xue Xue Bao; 1998 May; 33(5):373-8. PubMed ID: 12017006
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB
Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524
[TBL] [Abstract][Full Text] [Related]
13. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
Lutz VD; Gielsdorf W; Rasper J; Jaeger H; Loew D
Arzneimittelforschung; 1985; 35(4):730-4. PubMed ID: 4015739
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic properties of isosorbide-5-mononitrate under fasting and fed conditions in healthy male subjects.
Jin C; Jeon JY; Im YJ; Jeong JA; Kim Y; Chae SW; Bentz J; Kumke T; Kim MG
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):97-106. PubMed ID: 25492848
[TBL] [Abstract][Full Text] [Related]
16. [The evaluation of the bioavailability of isosorbide 5-mononitrate].
Dyderski S; Szkutnik D; Drobnik L; Szymańska-Shawkat E
Pol Merkur Lekarski; 1999 Aug; 7(38):64-6. PubMed ID: 10522420
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
Skutta T; Böttcher B; Brandt L
Arzneimittelforschung; 1989 Apr; 39(4):507-11. PubMed ID: 2751738
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration].
Keller-Stanislawski B; Marschner JP; Rietbrock N
Arzneimittelforschung; 1992 Jan; 42(1):17-20. PubMed ID: 1586374
[TBL] [Abstract][Full Text] [Related]
19. [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
Geigenberger A; Degen J; Maier-Lenz H
Arzneimittelforschung; 1982; 32(9):1138-40. PubMed ID: 6890839
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of isosorbide mononitrate.
Abshagen UW
Am J Cardiol; 1992 Nov; 70(17):61G-66G. PubMed ID: 1449102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
